AHSA1 as a prognostic biomarker and potential immunotherapeutic target in HNSCC: integrative bulk RNA-seq, scRNA-seq analyses and experimental validation
In HNSCC patients, AHSA1 might be a useful biomarker for prognostic evaluation and guidance for immunotherapy. Furthermore, inhibition of AHSA1 could effectively suppress tumor growth, invasion, and migration, underscoring its potential for HNSCC treatment strategies.
Authors
- Ran Chen (ORCID: https://orcid.org/0000-0002-0296-1724)
- Wenkai Huang (ORCID: https://orcid.org/0009-0001-3874-6065)
- Feihan Gu (ORCID: https://orcid.org/0000-0002-6982-1523)
- Siyuan Chen (ORCID: https://orcid.org/0000-0003-1126-6210)
- Weimin Bao (ORCID: https://orcid.org/0000-0001-7528-3832)
- Erli Wu
- Xiaorong Yan
- Wenhua Xu
- Yuanyin Wang
Institutions
- Anhui Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1186/s12885-025-14833-2
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00